Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows
Adding the lymphoma therapy vorinostat to Revlimid…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreAdding the lymphoma therapy vorinostat to Revlimid…
A new approach using genetically modified T-cells — via…
Nektar Therapeutics is launching a…
The U.S. Food and Drug Administration (FDA) has granted…
U.S. blood cancer specialists are aware of recent approvals…
Health Canada has approved Darzalex (daratumumab), in combination with…